David E. Burgio

Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials

Paul D. Miller, Christian Roux, Steven Boonen et al. · Journal of Bone and Mineral Research · 2005 · 317 citations · Full text

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

Pierre D. Delmas, Michael R. McClung, José Zanchetta et al. · Bone · 2007 · 97 citations

Bone Disease, Bone Health, Medicine +6

Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis

Robert A. Yokel, David D. Allen, David E. Burgio et al. · Journal of Pharmacological and Toxicological Methods · 1992 · 58 citations

Hemodialysis, Urology, Engineering +7

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Michael R. McClung, Ana Balske, David E. Burgio et al. · Osteoporosis International · 2012 · 47 citations · Full text

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

Michael R. McClung, Paul D. Miller, Jacques P. Brown et al. · Osteoporosis International · 2011 · 46 citations · Full text